Lv6
2548 积分 2021-10-19 加入
[Lorlatinib primary hospital patient health management expert consensus (2025 edition)]
3天前
已完结
Perioperative Considerations of Neoadjuvant and Perioperative Chemoimmunotherapy for Resectable Lung Cancer
19天前
已完结
Efficacy and safety of anti-PD-1 versus anti-PD-L1 in perioperative immunotherapy: A comprehensive reanalysis of randomized controlled trials
19天前
已完结
Efficacy of immune checkpoint inhibitors in the first line therapy of non-squamous non-small cell lung cancer: a systematic review and network meta-analysis
20天前
已完结
First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study
21天前
已完结
SPIRIT 2025声明：随机试验方案指南更新版 SPIRIT 2025 Statement: Updated Guideline for Protocols of Randomised Trials
22天前
已完结
PET/CT Radiomics-based assessment of tumor heterogeneity for predicting immunotherapy outcomes in advanced lung squamous cell carcinoma: a retrospective prognostic modeling study
25天前
已完结
Befotertinib (D-0316) versus icotinib as first-line therapy for patients with EGFR-mutated locally advanced or metastatic non-small-cell lung cancer: a multicentre, open-label, randomised phase 3 study
1个月前
已完结
Selpercatinib in Early-Stage RET Fusion–Positive Non–Small-Cell Lung Cancer
1个月前
已完结
Neoadjuvant Osimertinib for Resectable EGFR -Mutated Non–Small Cell Lung Cancer
1个月前
已完结
皖公网安备34019202002308
